Stockscreener 앱 받기
2.81
1.23%
-0.035
시간 외 거래:
2.77
-0.04
-1.42%
전일 마감가:
$2.845
열려 있는:
$2.81
하루 거래량:
132.27K
Relative Volume:
0.50
시가총액:
$11.24M
수익:
$895.50K
순이익/손실:
$-26.30M
주가수익비율:
-1.7134
EPS:
-1.64
순현금흐름:
$-23.84M
1주 성능:
-24.05%
1개월 성능:
-5.70%
6개월 성능:
-70.32%
1년 성능:
-90.46%
1일 변동 폭
$2.71
$2.85
1주일 범위
$2.71
$4.34
52주 변동 폭
$2.65
$40.40
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
2.81 | 11.24M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
422.27 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.40 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.07 | 34.90B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.37 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.30 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Maxim Group | Buy |
| 2024-11-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 개시 | H.C. Wainwright | Buy |
Mainz Biomed N V 주식(MYNZ)의 최신 뉴스
Mainz Biomed to hold annual meeting on June 2 By Investing.com - Investing.com Canada
Mainz Biomed to hold annual meeting on June 2 - Investing.com
Mainz Biomed Prepares for June 2025 Annual General Meeting - TipRanks
Stocks of Mainz Biomed N.V (MYNZ) are poised to climb above their peers - Sete News
Investing in Mainz Biomed N.V (MYNZ): What You Must Know - knoxdaily.com
MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus
Mainz Biomed Enters into Technology Partnership with EDX Medical Group - The Manila Times
Strategic Partnership: Mainz Biomed and EDX Medical Join Forces to Transform Early Cancer Detection in UK Market - Stock Titan
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for Co - GuruFocus
Mainz Biomed N.V (NASDAQ: MYNZ) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
Mainz Biomed advances in FDA approval for CRC test By Investing.com - Investing.com South Africa
Mainz Biomed advances in FDA approval for CRC test - Investing.com Australia
The Mainz Biomed N.V (MYNZ) Stock Is Headed for a Correction - uspostnews.com
MYNZ: Mainz Biomed Advances Cancer Detection with New Feasibilit - GuruFocus
Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire
Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 48.7% in April - Defense World
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - ADVFN
(MYNZ) Investment Report - news.stocktradersdaily.com
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - The Manila Times
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia
Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks
Mainz Biomed secures license for pancreatic cancer test - Investing.com India
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times
Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq
Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
(MYNZ) Trading Advice - Stock Traders Daily
Mainz Biomed N V (MYNZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.46%
자본화:
|
볼륨(24시간):